CONBA(SH:600572) Jin Rong Jie·2025-07-31 18:04Core Viewpoint - Kang En Bei's stock price experienced a decline of 1.06% on July 31, closing at 4.65 yuan, with a trading volume of 367,000 hands and a transaction amount of 171 million yuan [1] Company Overview - Kang En Bei operates in the pharmaceutical manufacturing industry, specifically within the traditional Chinese medicine sector, focusing on drug research, production, and sales [1] - The company's product range includes traditional Chinese medicine preparations, chemical raw materials and preparations, and biological products, indicating a comprehensive pharmaceutical industry chain [1] Recent Developments - On July 31, Kang En Bei announced that its wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Aminocaproic Acid Tablets, which are used to treat various bleeding symptoms caused by hyperfibrinolysis [1] - The research and development investment for this drug was approximately 6.27 million yuan, and it is considered to have passed the consistency evaluation for generic drugs [1] Market Activity - On the same day, the main funds for Kang En Bei saw a net outflow of 1.6435 million yuan, accounting for 0.01% of the circulating market value [1]